Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL1 | Q9BW60 | 2/20 | 0.62 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.58 |
| ▸ | MEN1 | O00255 | 7/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | PRKACA | P17612 | 3/20 | 0.55 |
| ▸ | WNT3A | P56704 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439214 | 0.90 | ELOVL1 (0.60) | ELOVL1ROCK1CYP3A4KMT2AMEN1 | |
| SCHEMBL436415 | 0.88 | WNT3A (0.69) | ELOVL1ROCK1CYP3A4KMT2AMEN1 | |
| SCHEMBL438743 | 0.88 | ELOVL1 (0.79) | ELOVL1ROCK1CYP3A4KMT2AMEN1 | |
| SCHEMBL439513 | 0.86 | ELOVL1 (0.62) | ELOVL1ROCK1CYP3A4KMT2AMEN1 | |
| SCHEMBL438731 | 0.86 | ELOVL1 (0.64) | ELOVL1ROCK1CYP3A4KMT2AMEN1 | |
| SCHEMBL439504 | 0.86 | ELOVL1 (0.64) | ELOVL1ROCK1CYP3A4KMT2AMEN1 | |
| SCHEMBL12124891 | 0.82 | ROCK1 (0.65) | ELOVL1ROCK1CYP3A4KMT2AMEN1 | |
| SCHEMBL436414 | 0.81 | ROCK1 (0.64) | ELOVL1ROCK1CYP3A4KMT2AMEN1 | |
| SCHEMBL14392969 | 0.81 | ROCK1 (0.64) | ELOVL1ROCK1CYP3A4KMT2AMEN1 | |
| SCHEMBL13213665 | 0.80 | ROCK1 (0.60) | ELOVL1ROCK1CYP3A4KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278306-B2 | C-met protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120065213-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058271-B2 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058271-B2 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2032562-B1 | SELECTIVE INHIBITORS OF ROCK PROTEIN KINASE AND USES THEREOF | VERTEX PHARMA (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2007133622-A2 | SELECTIVE INHIBITORS OF ROCK PROTEIN KINASE AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270386-A1 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-20070270386-A1 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270386-A1 | Selective inhibitors of rock protein kinase and uses thereof | ROCK1, ROCK2, MYLK | ELOVL1 2798/4885ROCK1 1/4885CYP3A4 4395/4885 |
| US-20120065213-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, MYLK | ELOVL1 3141/4885ROCK1 4/4885CYP3A4 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.